Royalty Pharma (RPRX) Profit After Tax (2019 - 2026)

Royalty Pharma has reported Profit After Tax for 8 years, with the latest figure at $294.7 million in Q1 2026.

• Quarterly Profit After Tax rose 23.12% year-over-year to $294.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $632.2 million (down 56.07% YoY) and the FY2025 annual result came in at $770.9 million, down 10.25% from the prior year.
• Profit After Tax rose to $294.7 million in Q1 2026 per RPRX's latest filing, from -$197.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at $1.1 billion in Q4 2023 and troughed at -$268.9 million in Q4 2022.
• A 5-year average of $261.1 million and a median of $208.2 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax tumbled 3501.47% in 2022, then surged 4909.4% in 2025.
• Over 5 years, Profit After Tax stood at -$268.9 million in 2022, then soared by 494.12% to $1.1 billion in 2023, then sank by 80.35% to $208.2 million in 2024, then slumped by 194.77% to -$197.3 million in 2025, then soared by 249.34% to $294.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $294.7 million, -$197.3 million, and $444.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.